uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
Show others and affiliations
2013 (English)In: International Journal of Breast Cancer, ISSN 2090-3170, E-ISSN 2090-3189, Vol. 2013, 582134- p.Article in journal (Refereed) Published
Abstract [en]

Introduction

About half of all new ipsilateral events after a primary ductal carcinoma in situ (DCIS) are invasive carcinoma. We studied tumor markers in the primary DCIS in relation to type of event (invasive versus in situ).

Methods

Two hundred and sixty-six women with a primary DCIS from two source populations, all with a known ipsilateral event, were included. All new events were regarded as recurrences. Patient and primary tumor characteristics (estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, and Ki67) were evaluated. Logistic regression was used to calculate odd ratios and 95% confidence intervals in univariate and multivariate analyses.

Results

One hundred and thirty-six of the recurrences were invasive carcinoma and 130 were in situ. The recurrence was more often invasive if the primary DCIS was ER+ (OR 2.5, 95% CI 1.2-5.1). Primary DCIS being HER2+ (OR 0.5, 95% CI 0.3-0.9), EGFR+ (OR 0.4, 95% CI 0.2-0.9), and ER95-/HER2+ (OR 0.2, 95% CI 0.1-0.6) had a lower risk of a recurrence being invasive.

Conclusions

In this study, comparing type of recurrence after a DCIS showed that the ER-/HER2+ tumors were related to a recurrence being a new DCIS. And surprisingly, tumors being ER+, HER2-, and EGFR- were related to a recurrence being invasive cancer.

Place, publisher, year, edition, pages
2013. Vol. 2013, 582134- p.
National Category
Basic Medicine
Research subject
Pathology
Identifiers
URN: urn:nbn:se:uu:diva-222151DOI: 10.1155/2013/582134PubMedID: 24490077OAI: oai:DiVA.org:uu-222151DiVA: diva2:710892
Available from: 2014-04-08 Created: 2014-04-08 Last updated: 2017-12-05

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Amini, Rose-MarieFjällskog, Marie-LouiseWärnberg, Fredrik

Search in DiVA

By author/editor
Amini, Rose-MarieFjällskog, Marie-LouiseWärnberg, Fredrik
By organisation
Department of Surgical SciencesDepartment of Immunology, Genetics and PathologyMolecular and Morphological PathologyOncologyEndocrine Surgery
In the same journal
International Journal of Breast Cancer
Basic Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 598 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf